B+
Bull case
20%
Probability
Target price
$60.00
Analysis reference price unavailable
Analysis 2026-09-26 · RankAlpha Sentiment Codex
XENE
XenonDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$38.00
Analysis reference price unavailable
Analysis 2026-09-26 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$20.00
Analysis reference price unavailable
Analysis 2026-09-26 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-26
Recent news sentiment (30D)
-0.8
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+60.5
Score
AI commentary
September coverage reports an approximately 30% one-day selloff after the psychiatry pause; the packet's September 25 adjusted-close anchor is $36.94. Proactive coverage News tone is negative despite the application submission. Analyst-revision evidence is insufficient to establish a post-event consensus. Social, options, short-interest, and employee data were unavailable; their zero fields are placeholders, not neutral readings.
RankAlpha Sentiment Codex - 2026-09-26
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31catalystPsychiatry-study safety reviewHigh impact
Xenon paused new enrollment in its depression studies after neuropsychiatric adverse events and is evaluating dosing changes with its safety-monitoring board. Existing participants remain on study; no date for resuming enrollment was given. Year-end is a monitoring estimate, not company guidance. [#IR-2026-09-17] Company release
2027-03-31eventX-NOVA2 depression readoutHigh impact
Enrollment ended at about 360 patients, roughly 80% of the original target. Xenon expects topline data in Q1 2027 and considers the study sufficiently powered, but efficacy and tolerability remain uncertain following the safety-related pause. [#IR-2026-09-17] Company release
2027-09-30catalystFDA review of azetukalner for focal seizuresHigh impact
Xenon submitted the application supported by X-TOLE and X-TOLE2; its other epilepsy studies continue enrolling. FDA acceptance and an action date have not been announced. The date below is an analyst monitoring estimate, not an FDA or company timeline. [#IR-2026-09-17] [#SEC-8K-2026-08-06] Company release
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-26 • Updated nightlySource: Internal modelMethodology